Acute Liver Failure Diagnostic Criteria and Management

Laboratory Criteria

• The American Association for the Study of Liver Diseases recommends evaluating renal function by assessing creatinine levels, with levels >132-170 mmol/L indicating associated renal compromise 1, 2

Classification and Prognosis Systems

• The King's College criteria for acute liver failure due to paracetamol include a pH arterial < 7.3 or lactate arterial > 3.5 mmol/L after fluid resuscitation, or the presence of three criteria: prothrombin time > 100 seconds, creatinine > 3.4 mg/dL 1, and encephalopathy grade III-IV 1
• For non-paracetamol-related acute liver failure, the King's College criteria include prothrombin time > 100 seconds or three or more of the following: age < 10 or > 40 years, etiology such as non-A, non-B hepatitis or idiosyncratic drug reaction 3, jaundice duration before encephalopathy onset > 7 days, prothrombin time > 50 seconds, and bilirubin > 17 mg/dL 1

CLIF-SOFA Score

• The CLIF-SOFA score evaluates the severity of organ failure, including liver (bilirubin levels), coagulation (INR), cerebral (encephalopathy grade), renal, circulatory, and respiratory functions 1, 2
• The liver component of the CLIF-SOFA score assigns points based on bilirubin levels: <20 mmol/L (0 points), >20-34 mmol/L (1 point), >34-102 mmol/L (2 points), >102-204 mmol/L (3 points), and >204 mmol/L (4 points) 1
• The coagulation component of the CLIF-SOFA score assigns points based on INR: <1.1 (0 points), 1.1-<1.25 (1 point), 1.25-<1.5 (2 points), 1.5-<2.5 (3 points), and ≥2.5 (4 points) 1

Diagnostic Considerations

• The European Association for the Study of the Liver suggests that in cases of suspected autoimmune hepatitis, liver biopsy may be necessary, preferably via the transjugular route in the presence of severe coagulopathy 3

Acute Liver Failure Criteria

Diagnostic Criteria

• The CLIF-SOFA system evaluates the severity of organ failure, assessing parameters such as liver function (bilirubin), coagulation (INR), cerebral function (grade of encephalopathy), renal function (creatinine), circulatory function (MAP or vasopressors), and respiratory function (PaO2/FiO2 or SpO2/FiO2) 4

Management

• Early transfer to an intensive care unit in a center with liver transplant capability is recommended 4
• The European Association for the Study of the Liver recommends antivirals for hepatitis B 5
• The American Association for the Study of Liver Diseases recommends evaluation for urgent liver transplant in patients with Wilson's disease 6

Prognostic Criteria

• Patients with acute liver failure who survive hospital discharge without transplant have a poor prognosis, with a 1-year survival rate of less than 25% 4
• These patients should be systematically referred to a liver transplant unit 4

Transplantation Criteria

• Patients who meet King's College criteria or have acute-on-chronic liver failure (ACLF) grade 2-3 according to CLIF-SOFA are candidates for liver transplant 4
• Patients with Wilson's disease who present with hemolysis, severe bilirubin elevation, and coagulopathy are also candidates for liver transplant 5, 6

Prognostic Significance of Bilirubin in Acute Liver Failure

Diagnostic and Prognostic Value

• The American Association for the Study of Liver Diseases (AASLD) identifies elevated bilirubin as a critical component for diagnosing acute-on-chronic liver failure (ACLF) 7, 8
• Rising bilirubin levels reflect the liver's diminishing capacity to process and excrete bilirubin, indicating progressive deterioration of hepatocyte function 8, 9
• Bilirubin elevation is typically accompanied by coagulopathy, which together constitute the laboratory hallmarks of liver failure 10, 8

Role in Severity Assessment and Scoring Systems

• The Model for End-Stage Liver Disease (MELD) score, which includes bilirubin as a component, may underestimate mortality in ACLF as it doesn't account for all extrahepatic organ failures 7

Clinical Implications and Monitoring

• Progressive increase in bilirubin levels indicates ongoing liver injury and may signal the need for more aggressive interventions 7
• Serial monitoring of bilirubin levels is essential to assess disease progression and treatment response 7

Special Considerations

• In Wilson's disease presenting as acute liver failure, bilirubin is typically markedly elevated with a predominant indirect fraction 11
• In drug-induced liver injury causing acute decompensation, bilirubin >2x ULN along with ALT >3x ULN and ALP >2x ULN is diagnostic 12, 13

Pitfalls and Caveats

• Bilirubin levels should always be interpreted in the context of other liver function tests and clinical parameters 7, 8
• Isolated hyperbilirubinemia may be due to Gilbert's syndrome or hemolysis rather than worsening liver function 14
• In ischemic hepatitis, serum bilirubin is usually <3 mg/dL despite marked elevations in transaminases and coagulopathy 11
• Bilirubin may be falsely elevated in patients with hemolysis, which should be excluded when evaluating acute liver failure 11

Management of Rising Bilirubin in Acute Decompensated Liver Failure

Assessment and Classification

• Rising bilirubin is a critical marker of worsening liver function in acute decompensated liver failure, with levels >6 mg/dL indicating liver failure according to the CLIF-Organ Failure score system 15
• Patients should be classified according to the ACLF grading system, with grades determined by the number of organ failures (ACLF I: single organ failure; ACLF II: two organ failures; ACLF III: three or more organ failures) 16

Initial Management

• Patients with rising bilirubin in acute decompensated liver failure should be admitted to intensive care or intermediate care units for close monitoring and management 15
• Early identification and treatment of precipitating factors is crucial, particularly bacterial infections, GI bleeding, drug toxicity, or viral hepatitis reactivation 15
• For patients with ACLF due to HBV reactivation, immediate administration of nucleoside analogues (tenofovir, entecavir) is strongly recommended 17, 18
• Organ function (liver, kidney, brain, lung, coagulation, circulation) should be monitored frequently as ACLF is a dynamic condition 15

Supportive Management

• Hemodynamic support: Monitor hemodynamic function and administer vasopressor therapy for marked arterial hypotension; avoid excessive volume expansion 15
• Respiratory support: Provide oxygen therapy and ventilation if respiratory failure is present; special care should be taken to preserve airway patency to prevent aspiration pneumonia 15
• Renal support: If kidney failure is present, identify and manage its cause accordingly; patients meeting criteria for hepatorenal syndrome should be treated with terlipressin and albumin or norepinephrine if terlipressin is unavailable 15
• Hepatic encephalopathy: Treat early with standard therapy to prevent aspiration pneumonia 15
• Coagulation management: For patients with coagulation failure, substitutive therapy should be given only if there is clinically significant bleeding 15

Liver Transplantation Evaluation

• Early referral to liver transplant centers for immediate evaluation is strongly recommended for patients with rising bilirubin and ACLF 17

Prognostic Considerations

• In patients who are not candidates for liver transplantation with four or more organ failures after one week of adequate intensive treatment, withdrawal of intensive care support can be considered due to futility 17

Special Considerations

• In Wilson's disease presenting as ALF, bilirubin is typically markedly elevated with a predominant indirect fraction due to hemolysis; treatment should include plasma exchange or albumin dialysis to lower serum copper, but recovery is infrequent without transplantation 18
• In autoimmune hepatitis causing ALF, liver biopsy (preferably via the transjugular route in the presence of severe coagulopathy) may be necessary for diagnosis, and corticosteroid therapy (prednisone 40-60 mg/day) should be initiated while placing the patient on the transplant list 18